The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 3 of the 15 sources its claims cite were checked for support.
Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies
Open accessAbstract
The perfusion medium is critical in maintaining high cell concentration in cultures for the production of monoclonal antibody by Chinese hamster ovary cells. In this study, the effects of perfusion culture strategies when using different media on the process stability, product titer, and product quality were investigated in 3-L bioreactor. The results indicated that continuous perfusion could maintain higher levels of cell density, product titer, and quality in comparison with those of the intermittent perfusion culture. Next, the perfusion culture conditions with different perfusion rates and temperature reduction methods were further optimized. When combining the high perfusion rates and delayed reduction of culture temperature at day 6, the product titer reached a higher level of 16.19 g/L with the monomer relative abundant of 97.6%. In this case, the main peak of the product reached 56.3% and the total N-glycans ratio was 95.2%. To verify the effectiveness of the optimized perfusion culture in a larger scale, a 200-L bioreactor was used to perform and the final product titer reached the highest level of 16.79 g/L at day 16. Meanwhile, the product quality (monomer abundant of 97.6%, main peak of 56.3%, and N-glycans ratio of 96.5%) could also be well maintained. This study provided some guidance for the high-efficient production of monoclonal antibody by CHO cells via optimized perfusion culture strategy.
Overview
CoChat Summary
TL;DR
Continuous perfusion outperformed intermittent perfusion for CHO-cell anti-PD-1 mAb production, and an optimized high-perfusion-rate strategy with delayed temperature reduction increased titer and maintained product quality. The optimized strategy was verified in a 200-L bioreactor, reaching 16.79 g/L at day 16 with comparable quality to the 3-L process.
Key findings
- Continuous perfusion maintained higher cell density, titer, and quality than intermittent perfusion: run #3 (intermittent) produced 4.39 g/L at day 14 versus 8.73–9.83 g/L in continuous runs #1–#4, and run #3 had the highest aggregate abundance at 3.5% versus 2.1%–2.2% in continuous runs #1–#2.
- The optimized 3-L strategy (run #8: higher perfusion rates plus temperature reduction at day 6) reached 16.19 g/L at day 16, with monomer relative abundance 97.6%, main peak 56.3%, and total N-glycans 95.2%; mAb production rate was 1.572 g/L/day.
- In the 200-L bioreactor (run #9), the final titer reached 16.79 g/L at day 16, comparable to run #8 (p > 0.05), with monomer 97.6%, main peak 56.3%, and total N-glycans 96.5%; pCO2 reached ∼175 mmHg after day 10, significantly higher than in the 3-L run #8 (p < 0.05).
- BM-II, FM-III, and FM-IV could replace the commercial media used in run #1; run #2 had a main peak of 55.4%, higher than run #1 and run #4 (both 49.5%), while run #4 had acidic variants at 27.5% and run #1 had basic variants at 28.4%.
Methods
- CHO cells producing anti-PD-1 mAb were cultured in 3-L bioreactors for runs #1–#8 and a 200-L bioreactor for run #9, using ATF with 50 kDa hollow fiber membranes; inoculation density was 1.5×10^6 cells/mL (2 L for 3-L runs, 180 L for the 200-L run).
- Culture conditions included pH 6.80–6.90, agitation at 250 rpm, DO at 40 ± 15% air saturation, initial temperature 36.5°C, and temperature reduction to 31.0°C at day 5 or day 6; perfusion rates and media varied across runs, with continuous versus intermittent perfusion compared.
- Analytics included daily VCD/viability, mAb titer by POROS A20 HPLC, SEC-HPLC for monomer/aggregate, CEX-HPLC for charge variants, HPLC-based N-glycan profiling, and glucose/lactate/osmolality/pCO2 measurements; data are mean ± SD of three biological independent experiments, with two-tailed Student’s t-test at p < 0.05.
Limitations
- The paper states that the effectiveness of the optimized perfusion culture strategy for other mAbs and recombinant biopharmaceutical proteins will be further investigated for process intensification.
- Evident from the design: the study tests only one anti-PD-1 mAb/CHO cell line and does not include a fed-batch comparator, so broader generalizability to other products or process modes is not established.
- Evident from the results: the 200-L run showed lower peak VCD than the 3-L run #8 (73.0×10^6 vs. 80.5×10^6 cells/mL) and higher pCO2 (∼175 mmHg after day 10), indicating scale-related differences that may affect process performance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
3 Valid · 0 Not valid · 9 Not checked · 88 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The VCD data of run #3 showed that intermittent perfusion could not elevate the cells density, which is mainly attributed to the nutrient shortage (Pérez-Rodriguez et al., 2020; MacDonald et al., 2021).”
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > 3 Results and discussion > 3.1 Production performance of mAb under CHO cell perfusion cultures using different media in 3-L bioreactor
What the sources say
- Partly supportedcites Pérez-Rodriguez et al., 2020 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says feeds replenish depleted nutrients and support cell growth and concentration. The paper does not examine the citing study’s run #3 or establish that nutrient shortage was the main reason intermittent perfusion failed to raise cell density. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites MacDonald et al., 2021 source
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“It was reported that lactate accumulation during cell culture could cause negative effects on CHO cells growth and mAb production (Konakovsky et al., 2016; Graham et al., 2019)”
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > 3 Results and discussion > 3.1 Production performance of mAb under CHO cell perfusion cultures using different media in 3-L bioreactor
What the sources say
- Supportedcites Konakovsky et al., 2016 source
The Introduction (§1.1; page unavailable) says lactate production negatively affects productivity and that the lactic-acid profile affects maximum cell count and final product titer. It identifies CHO cells and monoclonal antibodies as part of the production context, supporting the citing sentence’s hedged claim. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Graham et al., 2019 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results indicated that continuous perfusion could maintain higher levels of cell density, product titer, and quality in comparison with those of the intermittent perfusion culture.”
- Also stated in: § 3.1 Production performance of mAb under CHO cell perfusion cultures using different media in 3-L bioreactor · hedged
“The results indicated that continuous perfusion could maintain higher VCD levels (Figure 2A).”
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > Abstract
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.1 Production performance of mAb under CHO cell perfusion cultures using different media in 3-L bioreactor · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results indicated that continuous perfusion could maintain higher levels of cell density, product titer, and quality in comparison with those of the intermittent perfusion culture.”
- Also stated in: § 3.1 Production performance of mAb under CHO cell perfusion cultures using different media in 3-L bioreactor · plain
“the mAb production in run #3 was only 4.39 g/L at day 14, while the titer still reached to higher levels of 8.73–9.83 g/L in other three runs under continuous perfusion cultures”
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.1 Production performance of mAb under CHO cell perfusion cultures using different media in 3-L bioreactor · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this case, the main peak of the product reached 56.3% and the total N-glycans ratio was 95.2%.”
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
66 more claims
Create a free account to see all 100 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 7
- The quote only partly states this claim. 4
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > 3 Results and discussion > 3.2 Optimized CHO perfusion cultures for enhancing and stabilizing mAb production in 3-L bioreactor
“the relative abundance of monomer and aggregate maintained at similar levels of 2.3%–2.5% and 97.5%–97.7% in runs #5-#8”
§ Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies > 3 Results and discussion > 3.3 The mAb production performance under the optimized perfusion culture in 200-L bioreactor
“| Relative abundant (%) | Aggregate | 2.2 ± 0.11 | 2.1 ± 0.08 | 2.3 ± 0.07 | 2.3 ± 0.11 | | Relative abundant (%) | Monomer | 97.8 ± 2.10 | 97.9 ± 1.10 | 97.6 ± 1.24 | 97.6 ± 0.89 |”
Citations
Cites
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Protein aggregation and its inhibition in biopharmaceutics
Wang, W. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.014 · Cited by 983 · cited 1×
“Due to the vital role in therapeutic protein products, the aggregation of mAbs should be carefully investigated and analyzed (Wang 2005; Ha et al., 2022).”
BackgroundTherapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
Developments in therapy with monoclonal antibodies and related proteins
Shepard, H. M., Phillips, G. L., Thanos, C. D., & Feldmann, M. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-220 · Cited by 248
Scale‐up analysis for a CHO cell culture process in large‐scale bioreactors
Xing, Z., Kenty, B. M., Li, Z. J., & Lee, S. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22287 · Cited by 228 · cited 1×
“In addition, scaling up the production process in a larger bioreactor for verifying the effectiveness of process strategy is the crucial step for the commercial category (Xing et al., 2009; Vodopivec et al., 2019).”
MethodZhu, M. M., Goyal, A., Rank, D. L., Gupta, S. K., Boom, T. V., & Lee, S. S. (2008) · Biotechnology Progress · doi:10.1021/bp049815s · Cited by 199 · cited 2×
“It has reported that pCO2 could accumulate to the higher levels in large-scale bioreactors when the formed CO2 from CHO cells was not removed efficiently (Zhu et al., 2005).”
BackgroundDahodwala, H., & Lee, K. H. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.011 · Cited by 160 · cited 2×
“Recently, monoclonal antibodies (mAbs) and recombinant biopharmaceutical proteins (rBPs) have revolutionized the pharmaceutical industry (Dahodwala and Lee 2019; Zhang et al., 2021).”
BackgroundPrediction and Reduction of the Aggregation of Monoclonal Antibodies
van der Kant, R., Karow‐Zwick, A. R., Durme, J. V., Blech, M., Gallardo, R. U., Seeliger, D., Aßfalg, K., Baatsen, P., Compernolle, G., Gils, A., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.014 · Cited by 153
Karst, D. J., Serra, E., Villiger, T. K., Soos, M., & Morbidelli, M. (2016) · Biochemical Engineering Journal · doi:10.1016/j.bej.2016.02.003 · Cited by 151 · cited 1×
“Generally, scaling of the fed-batch process needs larger and more rigid layouts which limits its application (Karst et al., 2016; MacDonald et al., 2021).”
BackgroundAhn, W. S., Jeon, J., Jeong, Y., Lee, S. J., & Yoon, S. K. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.22006 · Cited by 132 · cited 1×
“In the perfusion mode, culture broth contained products and waste is perfused through the bioreactor under the perfusion controller, while the cells/products are retained or recycled back into the bioreactor (Ahn et al., 2008; MacDonald et al., 2021; MacDonald et al., 2022).”
Background
Cited by
Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells
Geng, S., Zhao, X., Zhang, X., Zhang, J., Mi, C., & Wang, T. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13008-6 · Cited by 51
“Therefore, PER culture is a relatively new technique to maintain cell viability and harvest high-quality proteins (Liang et al. 2023; Schwarz et al. 2023).”
Liu, M., Xiao, R., Li, X., Zhao, Y., & Huang, J. (2025) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.70078 · Cited by 45
Bioengineering lipid-based synthetic cells for therapeutic protein delivery
Siquenique, S., Ackerman, S., Schroeder, A., & Sarmento, B. F. C. C. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.08.004 · Cited by 14
Behboudi, A., Minervini, M., Badinger, Z. S., Haddad, W. W., & Zydney, A. L. (2024) · Protein Science · doi:10.1002/pro.5010 · Cited by 7
Advances in Serum-Free Suspension Culture Technology for Animal Cells and Their Applications
Ji, W., Chen, Z., Zhou, J., Yue, X., Qiao, Z., & Wang, J. (2025) · Vaccines · doi:10.3390/vaccines13111109 · Cited by 10
“For example, Lou et al. [36] developed a 5-”
Metadata
- Authors
- Liang, K., Luo, H., & Li, Q.
- Affiliations
- Jiangnan University (CN)
- Corresponding author
- Li, Qi
- ORCID
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-20
- Volume
- 11
- Pages
- 1112349-1112349
- ISSN
- 2296-4185 (ISSN-L)
- PMC
- PMC9895834
- OpenAlex
- W4317521338
- Cited by
- 37
- References
- 38
- Citations by year
- 2026: 18 · 2025: 9 · 2024: 8 · 2023: 2
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- monoclonal antibody production, CHO cells, perfusion culture, continuous perfusion, perfusion rate, product titer, bioreactor scale-up, process stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.